All Trials

A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared With Fluorouracil (5-FU) in Patients With Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with metastatic pancreatic adenocarcinoma progressing on gemcitabine (ECOG 0–1, limited comorbidities, adequate organ function) are randomized to glufosfamide 4500 mg/m2 IV q21d versus weekly bolus 5‑FU. Glufosfamide is an investigational oxazaphosphorine alkylating prodrug linked to glucose to enhance tumor uptake via GLUTs, releasing isophosphoramide mustard to form DNA crosslinks; key risks include renal tubular toxicity and myelosuppression.

ClinicalTrials.gov ID: NCT01954992

A Randomized Phase 2b/Phase 3 Study of the TGF-β2 Targeting Antisense Oligonucleotide OT-101 in Combination With mFOLFIRINOX Compared With mFOLFIRINOX Alone in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced, unresectable or metastatic pancreatic ductal adenocarcinoma (ECOG 0–1, RECIST-measurable) are randomized to mFOLFIRINOX with or without OT-101, an intravenous antisense oligonucleotide that downregulates TGF-β2 to counter tumor immune evasion and metastasis. Primary endpoint is overall survival, with key secondary endpoints of PFS and ORR.

ClinicalTrials.gov ID: NCT06079346

A Phase 2/3, Randomized Study to Evaluate the Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab in Subjects With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Treatment

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Untreated adults with unresectable/locally advanced or metastatic HCC (BCLC B–C; Child-Pugh A–B7; ECOG 0–1) are randomized to livmoniplimab (anti-GARP/TGF-β1) plus budigalimab (anti–PD-1) versus first-line immunotherapy standards (atezolizumab–bevacizumab or tremelimumab plus durvalumab). The study optimizes dosing in Stage 1 and then compares the selected combo against tremelimumab/durvalumab, treating until progression.

ClinicalTrials.gov ID: NCT06109272

An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced/metastatic or unresectable HCC or ICC with at least one measurable and injectable lesion; HCC cohort requires progression after ≥2 prior systemic lines (including prior IO/anti‑angiogenic), ICC cohort after first‑line chemo (with required prior IDH1 inhibitor if IDH1‑mutant and PD‑1 inhibitor if MSI‑H). Investigational therapy is intratumoral VG161, an engineered oncolytic HSV‑1 expressing IL‑12, IL‑15/IL‑15Rα, and a PD‑1/PD‑L1–blocking peptide, given as monotherapy or combined with nivolumab.

ClinicalTrials.gov ID: NCT05223816

A Phase 2, Open-label, Multicenter Study Investigating RP2 Oncolytic Immunotherapy in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable, Recurrent and/or Metastatic Hepatocellular Carcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable, recurrent, or metastatic HCC (Child-Pugh A, ECOG 0–1) who progressed after exactly one prior PD‑1/PD‑L1–based regimen and have measurable, injectable disease receive intratumoral RP2 plus atezolizumab and bevacizumab. RP2 is an oncolytic HSV‑1 engineered to express GALV‑GP‑R−, GM‑CSF, and a locally acting anti–CTLA‑4 molecule to drive oncolysis and antitumor immunity; key exclusions include high-risk varices, Vp4/macrovascular invasion, active herpetic infection, uncontrolled HBV, and significant autoimmune or bleeding risks.

ClinicalTrials.gov ID: NCT05733598

A Phase II, Open-Label, Multi-Drug, Multi-Center, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced hepatobiliary cancers: HCC cohorts receive volrustomig (PD-1/CTLA-4 bispecific) or rilvegostomig (PD-1/TIGIT bispecific) as monotherapy or combined with bevacizumab or lenvatinib, including a triple-immunotherapy/bevacizumab arm; BTC cohort (first-line) receives volrustomig or rilvegostomig with gemcitabine/cisplatin. Aims to assess response/PFS and safety of dual-checkpoint bispecifics, leveraging PD-1–anchored CTLA-4 or TIGIT blockade to enhance intratumoral T-cell activity.

ClinicalTrials.gov ID: NCT05775159

A Phase II Study of agenT-797 (Invariant Natural Killer T Cells), Botensilimab, a Novel Fc-enhanced CTLA-4 Inhibitor, Plus Balstilimab (Anti-PD-1) With Ramucirumab and Paclitaxel for Patients With Previously Treated, Advanced Esophageal, Gastric, or Gastro-esophageal Junction Adenocarcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable/metastatic esophageal, gastric, or GEJ adenocarcinoma after one prior line (or relapse ≤6 months after perioperative therapy), ECOG 0–1, receive ramucirumab plus paclitaxel combined with investigational immunotherapies: agenT‑797 (allogeneic invariant NKT cell therapy targeting CD1d-presented glycolipids), botensilimab (Fc‑enhanced CTLA‑4 inhibitor), and balstilimab (PD‑1 inhibitor). Excludes prior ramucirumab, recent taxane, severe prior irAEs from PD‑(L)1/CTLA‑4, active CNS mets, significant neuropathy, or active viral infections.

ClinicalTrials.gov ID: NCT06251973

A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable or metastatic ESCC after exactly one prior platinum-based chemo plus immune checkpoint inhibitor are randomized to ifinatamab deruxtecan, a B7-H3–targeted antibody–drug conjugate delivering a topoisomerase I inhibitor, versus investigator’s choice of docetaxel, paclitaxel, or irinotecan. Key eligibility includes ECOG 0–1, measurable disease, and exclusion of prior B7‑H3 or topo I agents and significant ILD/pneumonitis or CNS disease.

ClinicalTrials.gov ID: NCT06644781

A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic or unresectable gastric or GEJ adenocarcinoma that is CAPRIN-1–positive (≥30% cells at ≥2+) after prior therapy, ECOG 0–1, and candidates for ramucirumab/paclitaxel are randomized to ramucirumab/paclitaxel with or without TRK-950. TRK-950 is a humanized IgG1 monoclonal antibody targeting CAPRIN-1 designed to mediate ADCC/ADCP; doses tested are 5 or 10 mg/kg added to standard ramucirumab/paclitaxel.

ClinicalTrials.gov ID: NCT06038578

A Randomized, Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: First-line trial for adults with unresectable/metastatic HER2-positive, PD-L1 CPS ≥1 gastric/GEJ adenocarcinoma (ECOG 0–1) comparing: (A) rilvegostomig (bispecific PD-1/TIGIT antibody) + fluoropyrimidine + trastuzumab deruxtecan, versus (B) pembrolizumab + trastuzumab + FP or CAPOX, and (C) rilvegostomig + trastuzumab + FP or CAPOX. Key outcomes are PFS/OS; excludes significant autoimmune disease, ILD/pneumonitis risk, uncontrolled HBV/HCV, and LVEF <55%.

ClinicalTrials.gov ID: NCT06764875